Takeda Pharmaceutical Company Limited

Cardurion Pharmaceuticals, LLC

Akito Shibuya

Zenyu Shiokawa

Tomohiro Okawa

Yasufumi Miyamoto

Yusuke Tominari

Junya Shirai

Terufumi Takagi

Yusuke Sasaki

Nobuyuki Matsunaga

Yayoi Nakayama

Takashi Nakahata

Masato Yoshikawa

Masaki Seto

Kazuaki Takami

Yasuhiro Hirata

Michiyo Mochizuki

Seiji Miwatashi

Morihisa Saitoh

Tomohiro Seki

Yoshihisa Nakada

Kosuke Hidaka

Yuko Hitomi

Yasuo Nakagawa

Taisuke Kato

Koji Watanabe

Tsuneo Oda

Malcolm Maccoss

Masato Yoshida

Xiaolun Wang

Nobuyuki Takakura

Keiko Kakegawa

Nicholas Scorah

Minoru Yoshida

Hideki Furukawa

John S Tyhonas

Phong H Vu

Mark Sabat

Joanne Miura

Jumpei Aida

Rei Okamoto

Yoichi Nishikawa

Yuta Tanaka

Haixia Wang

Paul D Greenspan

Yoshito Terao

Tony Gibson

Lily Kwok

Brian Scott Freeze

Yasufumi Wada

Takafumi Yukawa

Mallareddy Komandla

Taisuke Tawaraishi

Takeshi Yoshikawa

Naoyoshi Noguchi

Shumpei Murata

Hiroki Takahagi

Paul Tanis

Atsutoshi Okabe

Takeshi Yamasaki

Hideo Suzuki

Norihito Tokunaga

Tsuyoshi Maekawa

Shizuo Kasai

Toshitake Kobayashi

Masanori Okaniwa

Yayoi Yoshitomi

Akira Kawada

The present disclosure provides a compound having a STING agonistic activity, which may be expected to be useful as an agent for the prophylaxis or treatment of STING-related diseases. The present disclosure relates to a compound represented by the formula (I): wherein each symbol is as defined in the description, or a salt thereof.

Methods of making a cyclic dinucleotide

The present invention provides a fused heteroaryl compound having a CaMKII inhibitory action, which is expected to be useful as an agent for the prophylaxis or treatment of cardiac diseases (particularly catecholaminergic polymorphic ventricular tachycardia, postoperative atrial fibrillation, heart failure, fatal arrhythmia) and the like. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the description,or a pharmaceutically acceptable salt thereof.

Substituted imidazo[1,2-b]pyridazines and [1,2,4]triazolo[4,3-b]pyridazines as CaMKII inhibitors

Antibody-drug conjugates comprising a cyclic dinucleotide

The present invention provides a compound having a CaMKII inhibitory action, which is expected to be useful as an agent for the prophylaxis or treatment of cardiac diseases (particularly catecholaminergic polymorphic ventricular tachycardia, postoperative atrial fibrillation, heart failure, fatal arrhythmia) and the like. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification,or a salt thereof.

Substituted amines for treating cardiac diseases

Provided is a novel aromatic ring compound which may have a GPR40 agonist activity and a GLP-1 secretagogue action. A compound represented by the formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof may have a GPR40 agonist activity and a GLP-1 secretagogue action, may be useful for the prophylaxis or treatment of cancer, obesity, diabetes, hypertension, hyperlipidemia, cardiac failure, diabetic complications, metabolic syndrome, sarcopenia and the like, and may afford superior efficacy.

Aromatic compound

The present invention provides a compound having a CaMKII inhibitory action, which is expected to be useful as an agent for the prophylaxis or treatment of cardiac diseases (particularly catecholaminergic polymorphic ventricular tachycardia, postoperative atrial fibrillation, heart failure, fatal arrhythmia) and the like. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.

Aminopyrimidine compound

Cyclic dinucleotide

The present invention provides a heterocyclic compound having an IRAK-4 inhibitory action, which is useful for the prophylaxis or treatment of inflammatory disease, autoimmune disease, osteoarticular degenerative disease, neoplastic disease and the like, and a medicament containing thereof. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.

Heterocyclic compound

Provided is a novel aromatic ring compound having a GPR40 agonist activity and a GLP-1 secretagogue action. A compound represented by the formula: wherein each symbol is as described in the DESCRIPTION, or a salt thereof has a GPR40 agonist activity and a GLP-1 secretagogue action, is useful for the prophylaxis or treatment of cancer, obesity, diabetes, hypertension, hyperlipidemia, cardiac failure, diabetic complications, metabolic syndrome, sarcopenia and the like, and affords superior efficacy.

Aromatic compounds with GPR40 agonistic activity

Provided is an aromatic ring compound having a GPR40 agonist activity. A compound represented by the formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof has a GPR40 agonist activity, and is useful as an agent for the prophylaxis or treatment of diabetes and the like.

Aromatic ring compound

Growing community of inventors

Kanagawa, Japan

Akito Shibuya